The Subventricular Zone in Glioblastoma: Genesis, Maintenance, and Modeling

Jamison Beiriger1,2, Ahmed Habib1,2, Nicolina Jovanovich1,2, Chowdari V. Kodavali1,2, Lincoln Edwards1,2, Nduka Amankulor1,2 and Pascal O. Zinn1,2*

1 Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States, 2 Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh PA, United States

Glioblastoma (GBM) is a malignant tumor with a median survival rate of 15-16 months with standard care; however, cases of successful treatment offer hope that an enhanced understanding of the pathology will improve the prognosis. The cell of origin in GBM remains controversial. Recent evidence has implicated stem cells as cells of origin in many cancers. Neural stem/precursor cells (NSCs) are being evaluated as potential initiators of GBM tumorigenesis. The NSCs in the subventricular zone (SVZ) have demonstrated similar molecular profiles and share several distinctive characteristics to proliferative glioblastoma stem cells (GSCs) in GBM. Genomic and proteomic studies comparing the SVZ and GBM support the hypothesis that the tumor cells and SVZ cells are related. Animal models corroborate this connection, demonstrating migratory patterns from the SVZ to the tumor. Along with laboratory and animal research, clinical studies have demonstrated improved progression-free survival in patients with GBM after radiation to the ipsilateral SVZ. Additionally, key genetic mutations in GBM for the most part carry regulatory roles in the SVZ as well. An exciting avenue towards SVZ modeling and determining its role in gliomagenesis in the human context is human brain organoids. Here we comprehensively discuss and review the role of the SVZ in GBM genesis, maintenance, and modeling.

Keywords: SVZ, glioblastoma, modeling, ventricular, organoid

INTRODUCTION

Glioblastoma (GBM) is the most common and most aggressive malignant glial tumor found in adults (1, 2). While prognosis varies with factors such as age and specific mutations (2-4), GBM remains an incurable tumor with a median survival of 9 months without treatment and 15-16 months with treatment (5-7). However, a small percentage of patients achieve long-term survival (>2.5yrs) (8, 9). Cases of longer-term survival and response to treatment provide hope that increasing knowledge of the disease pathology can lead to treatments with improved survival. Conventional treatment for GBM includes surgical resection followed by concurrent radiotherapy and temozolomide (TMZ) and subsequently, 6-12 cycles of TMZ (6, 10, 11). Aggressive tumor cell migration and growth preclude complete surgical resection, resulting in a near 100% relapse...
rate (12–15). Incomplete resection, post-operative recovery time, and neurologic deficits may delay subsequent treatment, thus, leading to GBM progression early within weeks of surgery or delayed within 2 years for a majority of patients (16, 17).

Cancer stem-like cells have been suggested as the origin of many cancers (18). Neural stem/precursor cells (NSCs), in particular, have been linked to cancer (19). Molecular evidence establishes a strong link between stem cells and cancer stem cells (20). Animal studies have corroborated this link, supporting a hypothesis of tumor origination from neural precursor cells (19, 21–23). Furthermore, a clinical report of neural precursor transplantation leading to the formation of donor cell-derived tumors demonstrates a possible stem cell origin of cancer in humans (24). Altogether, these findings provide strong support for NSCs as one of the cells of origin for cancer. Specifically, NSCs in the subventricular zone are implicated (25).

The subventricular zone (SVZ) is a 3-5mm layer between the lateral ventricle, corpus callosum, and striatum (26–28) that harbors the largest population of NSCs in the brain (3, 4, 29–32). The SVZ in humans is characterized by an astrocytic ribbon that is separated from a layer of ependymal cells by a hypocellular layer (33). The SVZ in animals differs in cellular composition and structure from the SVZ in humans (33–35).

Disease modeling towards identifying specific therapies for numerous cancers has been described (36). While numerous models have been developed for GBM research, faithfully recapitulating the microenvironment, structure, and molecular characteristics (36), GBM modeling has remained a challenge. Each model is unique and complex with benefits and drawbacks. Models range from in vitro cellular tumor systems to animal models (36). The recent advent of 3D models has increased the ability to effectively model the brain and associated tumors in the human context (37). These models more effectively simulate and maintain tumor structure compared to 2D models. However, challenges remain to model GBM, those include a lack of regionalized organoids and the underdevelopment of an immunological/inflammatory response, as well as the presence of only primitive vascular systems (37). It follows that utilizing a combination of models may be most apt for developing novel and effective therapeutic interventions.

Recent research has shed new light on the role of the SVZ in GBM (38, 39). This review addresses current hypotheses in SVZ involvement in gliomagenesis, maintenance, and modeling standards, as well as the capacity of current models to incorporate these hypotheses.

GLIOBLASTOMA CELL OF ORIGIN

Cancer cells expressing stem cell surface markers reside in brain tumors, comprising between < 1% of cancer cells in low-grade tumors and over 25% of cancer cells in high-grade tumors (40, 41). A connection between glioblastoma initiating cells (GICs) and NSCs has been identified, but the specific lineages downstream of GICs remain understudied (42). The GBM stem cell and the astrocyte dedifferentiation theory are the two prevailing hypotheses for the origin of GBM (43, 44).

Both of these theories serve to explain the presence of cancer stem cells within the tumor (45, 46). The astrocyte dedifferentiation theory relies on the multi-step process of tumorigenesis leading a mature astrocyte to dedifferentiate to become a malignant stem-like cell. This model is supported by recent experiments demonstrating the formation of tumors that are histologically similar to GBM after activation of oncogenes and suppression of tumor suppressor genes in astrocytes (47). These experiments show that genetic manipulation of astrocytes can lead to tumorigenesis. To induce GBM formation, both tumor suppressors and oncogenes must be manipulated in astrocytes, whereas progenitor cells only require oncogene activation (44, 47). This manipulation in astrocytes results in their acquisition of stem cell-like characteristics, offering one possible explanation for the similarities between GICs and stem cells (48, 49).

The glioblastoma stem cell theory proposes that GICs are derived from NSCs. NSCs are self-renewing, multipotent cells in the brain responsible for differentiating into neurons, astrocytes, and oligodendrocytes (50–52). These cells are most active during development; however, recent evidence has suggested small populations in specific stem-cell niches remain functional in the adult brain (53–57). As such, neurogenesis in the human brain continues throughout life (58, 59). The glioblastoma stem cell theory is based on a longstanding hypothesis that cancers arise from a stem-like cell population, and thus, that tumors contain a subset of multipotent cells with stem cell characteristics. In the case of GBM, partially differentiated glial cells including oligodendrocyte precursor cells (OPCs) and astrocyte precursor cells may contribute to or be responsible for tumorigenesis (38). Lee et al (38) proposed that the most likely pathogenesis involves driver mutations in NSCs that contribute to tumorigenesis after differentiation into the oligodendrocyte cell line. The presence of cells with stem cell-like characteristics has been identified in many cancers (60), including brain tumors (41, 44, 61). Clinical evidence supporting this theory includes the formation of a donor-derived brain tumor after NSCs were injected intracerebrally and intrathecally into an Ataxia Telangiectasia patient (24). This case example demonstrates a stem cell to tumor transition in the human brain. Considering the heterogeneity of GBM, each of these theories may contribute a portion of the total tumor population included in the category of GBM.

NEURAL STEM CELLS AND Glioblastoma stem cells are molecularily related

Many molecular characteristics are shared between GBM stem cells (GSCs) and NSCs. Genome-Wide CRISPR-Cas9 screens of NSCs and GSCs identified several genetic commonalities (20). SOCS3, a modulatory protein that is responsible for maintaining stemness in NSCs (62), was identified as a top-scoring...
GBM-specific fitness gene (20). Loss of function of SOCS3 leads to downregulation of multiple GSC fitness genes, upregulation of neuronal progenitor markers, and ultimately GSC differentiation (20). SOX2, another important NSC factor (63), is also a high-scoring fitness gene for both NSCs and GBM (20). Other genes with similar fitness scores in NSCs and GSCs include SQLE, CDK6, and DOT1L (20). Similar fitness scores in these genes provide evidence that developmental growth patterns are reactivated in GBM (20). Some genes with high fitness scores in GBM had low fitness scores in NSCs, including JUN and SOX9 (20). This could suggest that GBM-specific gene activation promotes the maintenance of GSCs (20). Stem cell gene networks, similar to those of non-transformed NSCs, generate and maintain GSCs (20).

Proteomic analysis similarly highlights the relationship between NSCs and GSCs (64–71). Of 108 proteins differentially expressed in GSC, NSC, and other tumor tissues, 22 were overexpressed in GSC and NSC but not tumor tissue. Most of these genes are involved in chromatin, mRNA, and DNA processing (64). Pathways necessary for self-renewal properties are common between NSCs and GSCs (66–72). One of the proteins overexpressed in GSCs and NSCs is vimentin (64, 73). Hepatoma-derived growth factor (HDGF), an angiogenesis-promoting factor, is expressed at normal levels in NSCs but is overexpressed and secreted in GSCs (64), indicating a potential oncogenic alteration of a normal NSC process. Overexpression of HDGF is implicated in various cancers (74–80) including GBM (64). In addition to HDGF, other growth factors associated with development are produced in GSCs including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-alpha (TGFα), and stromal-derived factor 1 (SDF1) (64, 81–84). A study specifically examining chromosome 19 proteins in GSCs found upregulation of multiple molecular patterns related to stemness and development (85). These molecular markers highlight the relationship between NSCs and GSCs, as well as the potential avenues for the transformation of NSCs to GSCs.

### Subventricular Zone

#### Human Subventricular Zone

The SVZ is the largest neural stem cell niche in the adult brain. In humans, the SVZ is divided into four regions comprised of different cell types. The ependymal layer (Layer I) is the cellular layer closest to the ventricle common to all areas of SVZ within the brain. The hypocellular layer (Layer II) borders the ependymal layer and consists of basal processes of ependymal cells, astrocyte processes, and diffuse astrocyte cell bodies. Opposite the hypocellular gap from the ependymal layer is the astrocytic ribbon of cells (Layer III). This is the proliferative region where astrocyte-like cells act as stem cells (33, 86). Layer IV is the transitional zone to the brain parenchyma. Myelinated neuronal processes and neuron bodies are abundant in this area (87) (Figure 1). The cytoarchitecture of the human SVZ is unlike any other studied mammals. Cell types present in this region include astrocytes, NSCs, neurons, ependymal cells, oligodendrocytes, OPCs, and neuroblasts with transitory amplifying progenitors noticeably missing (39). The human subventricular zone is unique in its organization and cellular composition making it difficult to translate research from animals to humans.

#### Subventricular Zone in Humans vs. Subventricular Zone in Animals

Structurally, the SVZ in studied animals differs quite significantly from the human SVZ. The SVZ in rodents is not separated into four distinct layers; in fact, no hypocellular zone exists in adult mice (34). The hypocellular zone is only reported in humans and bovines (88), with all other mammalian models having close contact between ependymal cells and NSCs (35). Another unique characteristic of the human SVZ is the astrocytic ribbon containing proliferative cells previously thought to be NSCs (33, 89). No progenitor cells or migration has been observed from this region, calling into question the activity of these “NSCs” (89). However, when cultured in vitro, astrocytes from

![FIGURE 1](https://www.frontiersin.org) | A schematic illustration depicting a coronal view of the subventricular zone (SVZ) neurogenic niche in the adult human brain.
the SVZ, the striatum has cells co-expressing the neuroblast markers DCX and PSA-NCAM, indicating migration to this region (129). Carbon dating of a subpopulation of DARP23-negative interneurons in striatum demonstrates a 2.7% turnover rate, significantly higher than that of the OB (< 1% over 100 years). Furthermore, recently developed striatal neurons and neuroblasts co-express the markers calretinin and neuropeptide Y, supporting an SVZ origin for striatal neurogenesis (129). Other animals demonstrate decreased striatal neurogenesis compared to humans (130–135). Research in mice found Notch-dependent local astrocyte-mediated neurogenesis in the striatum (136). It is unclear the extent to which this occurs in humans (135). These differences highlight the challenges involved with translating animal research to humans in this area.

**Additional Elements of the Subventricular Zone**

The following elements of the SVZ have been established in non-human mammals, but the extent to which they are present in the human SVZ is unclear. The SVZ stem cell niche is comprised of various cellular and acellular components along with the major cell types. Blood vessels influence differentiation and migration patterns in this niche. Brain-derived neurotrophic factor (BDNF) signaling guides neuroblast migration parallel to blood vessels adjacent to the SVZ (92, 137, 138). The SVZ has a leaky blood-brain barrier, permitting neural progenitor cells (NPCs) of the SVZ to respond to signals in the blood more readily (95). SVZ cells are drawn to blood vessels by molecules secreted by endothelial cells (139). Endothelial cells also promote neuroblast proliferation (94, 95, 140) and influence cell migration to and from the niche through SDF1/CXCR4 signaling (139). An extensive basal lamina contacts nearly every cell in the SVZ providing an avenue for molecular signaling to the entire niche (141, 142). These extracellular matrix structures, called fractones, bind growth factors and modulate NSC proliferation in the SVZ (143). Fractones are fractal-like structures consisting of laminins, collagens II and XVIII, nidogen, HSPGs, and perlecans (143). Laminin constructs both NSC and cancer stem cell (CSC) niches (144, 145) and supports stem cell renewal (146). Additionally, laminin interaction with integrin α-6 is important for the maintenance of NSCs and CSCs (147). Non-stem tumor cells produce laminin α-2, which permits GBM stem cell growth (148).

Macro-structure of the SVZ also facilitates signaling and subsequent cellular responses. Viewed from the ventral surface, the SVZ is organized in pinwheel structural units composed of ependymal cells spiraled around astrocytic processes. Cells in the pinwheels are connected by adherens junctions. Adherens junctions allow one daughter cell to remain a stem cell while the other differentiates into a progenitor. The pinwheel structure is important for stem cell proliferation and is characteristic of other stem cell niches in the body (149).

Gliogenesis is prominent in the developing SVZ from embryonic day (E) 90 until after E125. The SVZ serves as the origin of many of the glial cells in the mammalian brain (150–152). Studies examining multiple sclerosis and the rodent
OB indicate that gliogenesis in the SVZ continues in adults (153, 154) and evidence indicates that injury in the adult brain leads to increased gliogenesis from the SVZ (155, 156). Galectin-3 (Gal-3), up-regulated in brain injury, inflammation, and cancer, has a suggested role in modulating both neurogenesis and gliogenesis in the adult SVZ (157).

**NEURAL STEM CELLS IN THE SUBVENTRICAL ZONE IMPLICATION IN THE ORIGIN OF GLIOBLASTOMA**

**Subventricular Zone Neural Stem Cells Play a Role in Tumorigenesis**

Genomic and proteomic analyses of GBM and the SVZ have supported an association between the two. Recent molecular and genetic analysis of human GBM by Lee et al. (38) backs the theory that GBM develops from NSCs in the SVZ. They described direct molecular and genetic evidence from glioblastoma patients’ tissue and mouse models that there were astrocyte-like NSCs in the SVZ that could be the cell of origin. These cells contain the main driver mutations known to form GBM in humans. In their experiment, they performed sequencing of patient-matched tissues types (normal SVZ tissue, tumor tissue, and normal brain cortex or blood) from 28 patients with variable genetic profiles including isocitrate dehydrogenase-1 wild type (IDH-WT). They concluded that low-level driver mutations of GBM were present in the non-tumor SVZ tissue in 56.3% of IDH wild-type patients. Furthermore, single-cell sequencing and laser microdissection analysis of the obtained brain tissue as well as genome editing of their mouse model showed astrocyte-like NSCs carry driver mutations that lead to the development of high-grade gliomas (38). Additionally, extensive analysis of 28 tumors from both adults and children by Neftel et al. (158), indicates the presence of four cellular states that drive GBM malignant cells heterogeneity. These cellular states are associated with cycling cells representing mostly NPC-like and OPC-like states, particularly in pediatric tumors. Earlier reports of lineage tracing methods (159) also revealed significant aberrant growth prior to malignancy in OPCs. These findings suggest OPCs could be the major source of malignancy though initial mutations could occur in NSCs. This highlights the importance of analyzing premalignant states to identify the cancer cell of origin.

SVZ-related markers, such as GFAP and vimentin, are upregulated in GBM (160). This association supports the hypothesis that tumor cells in GBM are most related to the SVZ cells (160). Specifically, neuroblasts in GBM contain high levels of c-Myc, implicating the population of SVZ cells with high c-Myc expression in oncogenic transformation (160). In fact, overexpression of c-Myc may play a role in tumorigenesis and migration as it is expressed in SVZ cells with migratory potential (160).

Furthermore, restriction of proteases in GBM inhibits tumorigenesis, providing support for the theory of long-distance migration of GBM pathogenesis. Genomic investigation of SVZ-associated GBM supports this analysis, identifying genes commonly altered in SVZ and GBM (161). Differences between SVZ+ (SVZ-associated GBM) and SVZ- (Non-SVZ-associated GBM) GBM have also been observed (161). Notch signaling upregulation in SVZ+ GBM is correlated with Notch upregulation in the SVZ. The differential expression of various Notch signaling molecules is associated with predictable prognostic factors, including overall survival (OS) and progression-free survival (PFS) (162).

Proteome analysis of SVZ+ serum and tissue shows increased acute-phase proteins, lipid carrying proteins, and increased regulatory proteins potentially implicated in increased SVZ+ aggressiveness (163). CD133 expression, which is associated with a shorter time to distant recurrence, is greater in SVZ+ tumors (determined by imaging) than in SVZ- tumors (164). Additionally, the prognosis for GBM is strongly associated with the intracranial location in relation to the SVZ. Tumors contacting the SVZ have worse OS and PFS compared to more distant GBM (165). Furthermore, recurrence of GBM is significantly associated with neurogenic regions (12). The niche factors secreted by the SVZ promote proliferation and migration of GBM progenitor cells, promoting tumor growth and progression (166, 167). In contrast, the hippocampus is often spared from GBM invasion, possibly due to a less compatible extracellular matrix (ECM) (168). Furthermore, NSCs in the hippocampus are less likely involved in tumorigenesis. There are a few factors that differentiate NSCs in the SVZ from hippocampal NSCs in the subgranular zone (SGZ). Like NSCs in the SVZ, hippocampal NSCs have an apical process that contacts blood vessels; however, their basal process contacts neurons and glial cells (169, 170). These stem cells lack CSF contact which is normally a source of factors moderating proliferation for NSCs in the SVZ (25, 171). Abnormal signaling from the CSF is a potential mechanism for malignant transformation (25). Additionally, NSCs in the SGZ only differentiate into local granule neurons. The SGZ niche promotes differentiation without migration, whereas the SVZ promotes proliferation and migration while restricting differentiation (25).

Commonalities of GSCs and NSCs in the SVZ include nestin expression, proliferation capability, high motility, diverse progeny, association with vasculature, and communication with other niche components (25, 172). Much like NSCs (173, 174), GSCs rely on endothelial cells for factors promoting self-renewal, tumorigenicity, and survival (175–177). GSCs are also able to recruit microglia through cytokine production (178–180), which in turn promote tumor growth through angiogenesis and trophic factors (181). Much like in the tumor niche, NSCs and microglia regulate each other in the SVZ (182). Additionally, astrocytes and ECM proteins support the proliferation of both GSCs and NSCs (183–186). These similarities highlight the likeness the tumor niche displays for the SVZ. One notable difference is the lack of CSF within close proximity to cells within the tumor niche, which may contribute to the tumor pathology due to absence of regulation from CSF signaling (25).

Tumorigenesis experimentation in mice supports the theory that GBM-like invasive tumors originate in the SVZ. High-grade tumors are formed from NSCs/NPCs in mouse models after...
Migration. Migration occurs following the leader cell creation of an infiltrative path. Most infiltrations occur along blood vessels, fiber tracts, or over the surface via the subarachnoid space (187). In mice, SVZ cell migration occurs through the rostral migratory stream to many areas including the OB, hippocampus, and striatum. These cells have more migratory potential than other NPC niches, traveling further and to more locations (153). Neuroblasts have been identified in high numbers between the SVZ and the tumor in mice models, indicating SVZ cell migration to the tumor. Upregulation of neural precursors in the ipsilateral SVZ in mice with tumors contributes to this hypothesis (188). Follistatin secretion from NPCs decreases tumor growth and can even inhibit tumor growth in vitro (189). Follistatin expression by NPCs in the SVZ may explain why migration occurs before tumorigenesis. Neural precursor cell migration from the SVZ to the tumor zone is a critical finding in the pathogenesis of GBM tumors. This pathway represents an important target of future therapy and more models are needed to further investigate this relationship.

**Common Genes Implicated in Glioblastoma Play a Role in the Subventricular Zone**

There are several common mutations associated with human GBM. Primary GBM is classified by de novo mutations without evidence of a prior lesion (160). Primary GBM typically results from epidermal growth factor receptor (EGFR) amplification and loss of PTEN (190), while secondary GBMs result from IDH1 or IDH2 mutations (191, 192). Inactivation of TP53 (23), PTEN (193), and mutations in telomerase reverse transcriptase (TERT) (194, 195) are also commonly thought to contribute to the pathogenesis of GBM. Each of these genes, with the exception of IDH1, is known to be involved in the control of the SVZ NSCs (160). Matarredona and Pastor (25) recently reviewed some of the most common genetic mutations and their involvement in implicating the SVZ in GBM development.

Epidermal Growth Factor (EGF) induces proliferation and inhibits differentiation of NSCs in the SVZ (196–198). Amplification of the EGFR gene has been proposed as a potential mechanism for the development of GBM because of its role in the SVZ (160, 199). Both TP53 and PTEN are tumor suppressor genes. TP53, which modulates cell division, differentiation, and proliferation in the SVZ, is commonly mutated in both primary and secondary GBM (23, 190, 200–202). PTEN is involved in regulating migration, apoptosis, and proliferation for NSCs in the SVZ (203, 204). Knockout of TP53 or PTEN induces proclivity towards oncogenic transformation (193, 205). In adult mammals, telomerase expression is restricted to the OB and the SVZ (206), where it permits the growth and survival of NSCs (207). TERT is frequently upregulated in cancers (208), including more than half of GBMs (194, 209). In a study of human GBM mutations in IDH1 wild-type, the tumor-free SVZ had TERT promoter mutations, suggesting this could be an early mutation in the progression from NSC to GBM (38, 194).

While IDH1 has no known direct influence on the SVZ, IDH1 mutation is correlated with platelet-derived growth factor (PDGF) expression in GBM (210). PDGF promotes the proliferation of NSCs in the SVZ (211). Some other factors and pathways commonly altered in GBM and SVZ include c-Met, FoxO3, the Wnt pathway, and the sonic hedgehog pathway (160, 172, 212–216). These mutations provide strong evidence that SVZ NSCs are the origin of GBM in humans and accentuate pathways that could be targeted with therapeutics.

**Clinical Significance of the Subventricular Zone in Glioblastoma**

Understanding the role of the SVZ in GBM provides significant clinical value. Proposed therapy for GBM includes administering radiation to the SVZ to prevent tumor reoccurrence. So far, the reported effect of SVZ irradiation on outcomes in GBM patients has been inconsistent. In a meta-analysis of four studies observing the effects of high vs low dose radiation on prognosis, increased radiation dose to the ipsilateral SVZ significantly increased PFS while failing to significantly improve OS (217). Irradiation dose to the contralateral SVZ did not significantly improve PFS. Contralateral SVZ radiation dose effect on OS was not analyzed as it did not meet the study’s inclusion criteria. Higher cutoffs for “high dose irradiation” in the various studies correlated with increased PFS and OS as compared to lower cutoffs (217). Gupta et al. (218) found increased OS with increased radiation to the ipsilateral SVZ but decreased OS with increased radiation to the contralateral SVZ. Consistent with the results described above, Rizzo et al. (219) showed that increasing bilateral SVZ radiation dose directly correlates with increased PFS and OS. Furthermore, they found that a high radiation dose to the ipsilateral SVZ is associated with increased PFS and that there is no correlation between the dose administered to the contralateral SVZ and OS or PFS (219).

Gross total resection (GTR) may account for some of the variations in the results, as Chen et al. (220) found that high dose irradiation of the SVZ improves PFS only in patients with GTR, not in patients with subtotal resection or biopsy. In patients with GTR, PFS and OS were both improved with high-dose irradiation when compared to low-dose irradiation. This suggests that residual tumors may be responsible for recurrence in irradiated patients without GTR, and therefore, that irradiation may potentially prevent GBM recurrence originating from the SVZ (220). CXCL12 mediated upregulation of mesenchymal traits protects GSCs located in the SVZ from radiation, potentially explaining the increased effectiveness of higher doses of radiation (221). These data point to promising evidence that links radiation of areas of the SVZ to increased measures of survival and highlight the importance of studying GBM in the context of the SVZ. By means of human cerebral organoid SVZ models, we hope to expand on the research that has highlighted this relationship between the SVZ and GBM prognosis (Figure 2).

**MODELS**

There are several different methods of modeling GBM. Robertson et al. (36) organize GBM models into five separate categories: Patient-derived glioblastoma cell lines are cultured...
They have assumed a differentiated state that may no longer resemble GBM, but rather grow as an encapsulated tumor away from the parent tumor (36, 222, 224). Unlike classic cell lines, patient-derived GBM cell models retain the genetic and transcriptional state of the parent tumor, when cultured in similar conditions, long term (41, 61, 65, 225, 226). Cultures are deemed viable for long-term self-renewal after 10 passages which equate to at least 2 months in culture and can be frozen for long-term preservation (227). In one study, eight out of nine patient-derived models that lasted at least 8 passages were still viable after 50 passages (228). However, in practice low passage cultures are always archived. Patient-derived GBM cell models were originally grown as neurospheres in suspension culture, but the suspension is not necessary for survival and expansion. Adherent cultures are viable, permitting easier experimentation with these models (147, 229, 230). Additionally, adherent cultures were effective in deriving new cell lines in >90% of cases when using IDH-WT GBM cell lines (36, 224, 226). While adherent cultures are often easier to manipulate and study, suspension cultures can be developed into organoid models. These models are discussed more in a later section.

**Patient-Derived Glioblastoma Cell Lines**

*In vitro* models are often the simplest models. They involve culturing and experimenting on cell lines meant to represent GBM. Investigators have the choice of experimenting on widely used highly passaged ‘classic’ cell lines or patient-derived models such as low passage primary cell lines or tumor tissue slice cultures. The reliability of classically used cell lines, and the tumors they produce, have been called into question because they have assumed a differentiated state that may no longer resemble GBM, but rather grow as an encapsulated tumor away from the parent tumor (36, 222, 224).

Unlike classic cell lines, patient-derived GBM cell models retain the genetic and transcriptional state of the parent tumor, when cultured in similar conditions, long term (41, 61, 65, 225, 226). Cultures are deemed viable for long-term self-renewal after 10 passages which equate to at least 2 months in culture and can be frozen for long-term preservation (227). In one study, eight out of nine patient-derived models that lasted at least 8 passages were still viable after 50 passages (228). However, in practice low passage cultures are always archived. Patient-derived GBM cell models were originally grown as neurospheres in suspension culture, but the suspension is not necessary for survival and expansion. Adherent cultures are viable, permitting easier experimentation with these models (147, 229, 230). Additionally, adherent cultures were effective in deriving new cell lines in >90% of cases when using IDH-WT GBM cell lines (36, 224, 226). While adherent cultures are often easier to manipulate and study, suspension cultures can be developed into organoid models. These models are discussed more in a later section.

**Engineered Glioblastoma-Like Cell Lines**

GBM can also be engineered *in vitro*. Introduction of driver mutations stepwise into NSCs or other cells, *in vitro*, can cause these cells to transform phenotypically into cancer cells. They can then be transplanted and studied *in vivo* (36). Various methods such as plasmid transfection, lentiviral or retroviral transduction (48), and CRISPR/Cas9 technology (231) are used to induce these mutations and produce a GBM-like phenotype. CRISPR/Cas9 technology enables gene knock-out/in and more precise insertions/deletions compared to previous methods. It also allows for more experimental control through novel genetic screening techniques *in vitro* and *in vivo* (232, 233). CRISPR is effective for genetic manipulation of both human and mouse NSCs and could be used in a variety of future experiments towards this (36, 234). Additionally, it has been used to induce tumorigenesis in organoid models by knocking out tumor suppressor genes. The resulting tumor cells are molecularly similar to GBM and can be implanted into mice to grow into tumors (235, 236).

**FIGURE 2** The subventricular zone (SVZ) of a mature cortical organoid highly resembles the (SVZ) of an adult human brain. Positive immunofluorescence signatures of the common (SVZ) markers are represented in (A–D). NESTIN (Green) is an intermediate filament protein that is expressed by neural stem cells (NSCs) in the subventricular zone (SVZ) and it is generally recognized as a marker of undifferentiated nervous system cells. CD31 (Red, (A)) also known as Platelet endothelial cell adhesion molecule-1 (PECAM-1), is a glycoprotein highly expressed on endothelial cells and it is generally recognized as blood vessel markers. SOX-2 (Red, (B)) is an HMG-Box transcription factor that is expressed in neural progenitor cells and is considered as a marker of high pluripotency. Beta-Tubulin III (Red, (C)) is a marker for the glial fibrillary acidic protein expressed by astrocytes and ependymal cells during development. (Source Zinn lab).
Ex Vivo Animal Models

Ex vivo modeling is a popular neuroscience procedure adapted for GBM study (36, 237). Mice are the most common model due to their short breeding times, relatively low cost, easy genetic manipulation, and mammalian organ systems (36). Both slice culture methods and whole animal models can be studied. Slice culture methods allow accurate microanatomical analysis of tissue-tumor interaction, which provides insight into the interaction between GBM and the SVZ (238). However, whole animal models are often necessary as comprehensive disease-relevant models (36). Both tumor cell transplantation and genetically manipulated de novo tumors are viable methods of tumor induction of GBM in vivo.

In Vivo Tumor Transplantation Models

Tumor cells are directly transplanted into the brain or the skin in in vivo tumor transplantation models via orthotopic or subcutaneous injections. Orthotopic grafts are preferred due to spatial and temporal selectivity which allows for the induction of similar tumor physiology in multiple mice (36). Some drawbacks of orthotopic grafts include the technical challenge of implantation, lack of control over engraftment and seeding, and disruption of normal tissue architecture where the injury is caused by the injection procedure. Subcutaneous grafts are easier to introduce but lack the specific brain microenvironment and infiltration characteristic of GBM (239). Patient-derived orthotopic xenografts (PDXO) models involve the implantation of human tumor cells into immunocompromised mice, potentially simulating the tumor microenvironment of human GBM (36). Golebiewska et al. (240) reported the generation of a unique set of organoids and patient-derived xenografts of various glioma subtypes and corresponding longitudinal PDOX from primary and recurrent tumors. The model they presented captured a wide spectrum of the molecular genotypes of GBM that highlights the potential of these models for precision medicine. The mutations described in their models include: IDH1, ATRX, TP53, MDM2/4, amplification of EGFR, PDGFRA, MET, CDK4/6, MDM2/4, and of CDKN2A/B deletion, PTCH, and PTEN. With regards to the corresponding PDXO model, they found that it recapitulates the limited genetic evolution of gliomas in patients following treatment. The model they presented showed a clinically relevant response to TMZ and targeted therapies and could be used as a starting point to develop more advanced models that may help develop a therapeutically effective GBM precision treatment modality.

Genetically Engineered Mouse Models

GEMMs are created by introducing germline genetic mutations of tumor suppressors and oncogenes. This can occur via mutagen exposure (241), Cre-lox recombination (19), lentivirus administration (242), or CRISPR technology (36, 243). Selective breeding allows for the maintenance of mice litters with reproducible, mutated genotypes that are more susceptible to developing tumors and are useful for experimentation (36). These models provide insight into initiation events and driver mutations for GBM. A GEMM study revealed NF1 as a driver mutation for malignant astrocytoma (244), contributing to the subsequent discovery of NF1 as a driver mutation in GBM (245). Other work with GEMMs supports the theory that GBM derives from NSCs in the SVZ (242, 246–248). These studies found that NSCs are easier to transform to tumor cells than astrocytes are (242, 246, 248) and that expression of an IDH1 mutation in the adult SVZ can model gliomagenesis (247).

Organoids

Three-dimensional organoid models are some of the most useful models for studying GBM. Lancaster et al. (249) developed the first organoid model in 2013 by creating neuroectoderm tissue from induced pluripotent stem cells (iPSCs) and then suspending this tissue in a rotating bioreactor to enhance growth. These models recapitulate the cellular heterogeneity and structure seen in vivo (249). Organoids can either represent a brain structure or a tumor cytoarchitecture by culturing iPSCs or GSCs respectively (250). Eventually, the model develops to contain differentiated cells of various populations, mirroring the microenvironment of the brain, or tumor, structure. Organoid models allow cells representing a large spectrum of differentiation to coexist within a model (250). Additionally, primary tumors are able to grow to size in organoid models allowing expression of necrotic and hypoxic features of human tumors (250). These features can create a relatively realistic experimental model of a tumor in the human context; however, there are limitations to this model system. Cerebral organoid models take months to culture and can be highly variable, as well as often lack functional vasculature or immune responses (36). Despite these drawbacks, we believe human cerebral organoid technology is an excellent adjunct model system to the current models described above. Other models remain important as adherent cultures are used when a more reductionist model is needed and suspension cultures are used when a more comprehensive heterogenic model is necessary.

Azzarelli et al. (37), identified five different methods developed to create organoid models: (1) adding minced GBM specimen to Matrigel (250), (2) culturing extracted tumor into a matrigel-free serum-free environment on an orbital shaker (251), (3) nucleofecting embryonic stem cell brain organoids (235, 236), (4) adding 2D cultured patient-derived GSCs to embryonic stem cell brain organoids (236, 252), (5) and 3D bioprinting of GBM and endothelial cells with added ECM components (253). Preference for 3D organoid models stems from their ability to potentially recapitulate in vivo response to therapy more accurately than other models such as 2D cultures and PDOXs (235, 250, 252). Additionally, organoids are advantageous because they are able to culture a heterogeneous population of cells in the same environment (37). This allows CSC heterogeneity and development to be studied in the proper environment surrounded by a heterogeneous population of cells (37, 254). Recent techniques have enabled the creation of organoid models within 2-1 weeks (251), dramatically reducing the previous procedural time of multiple months (235, 236, 250, 252). This time reduction is key for therapeutic relevance because patients may begin treatment 1-2 weeks after surgical resection (37).

Some future challenges for 3D models include maintaining tumor complexity, establishing a microenvironment to mimic...
inflammatory responses, and reducing variability (255). A combination of models that takes advantage of each model's strengths may be most beneficial (37). In some cases, tumors were unable to develop despite genetic alterations consistent with pathogenesis (255). Regionalized organoids for the area of origin of a particular tumor may be required to solve this problem (255–258). It follows, that if human cerebral organoids do demonstrate a relatively faithful microarchitecture and presence of various differentiated cell types, that organoids may be an ideal model to study the human SVZ and how it relates to gliomagenesis.

**Subventricular Zone Organoid Models**

Organoid models have a variety of uses at various stages of research. Kim et al (259) reasons that organoid research is useful in four capacities: basic research, biobanking, disease modeling, and precision medicine. Given the clinical and basic science evidence supporting an association between the SVZ and GBM, an organoid model that accurately resembles the SVZ would be extremely valuable for the study of GBM. In the basic research sense, such a model may provide a comprehensive picture of gliomagenesis from driver mutations to tumor formation, unlike any other model. Biobanking is critical to improving standardization of study, allowing for research on tumors from patients with naturally developed tumors. Ideally, this model should reliably mimic both structural and cytoarchitectural components of the human SVZ to allow for analysis of the involvement of various niche components in GBM formation and maintenance. Heterogeneity in organoids permits additional factors such as immunologic response to be incorporated to judge their influence on the tumor within the simulated environment (260). Using an SVZ model, therapeutic strategies can be tailored to and tested on tumors in the early stages of development. Organoid models have the advantage of being created using iPSCs from a patient in just a few weeks to allow for the personalization of the treatment regimen for a tumor with specific mutations (261). The SVZ, in particular, is important to study in this context as this is where the earliest mutations are hypothesized to occur meaning this could be the earliest therapeutic target.

Current regional organoid models for the SVZ have some difficulties for GBM research purposes. The Qian et al. (262) model includes SVZ specific cells but lacks non-neurally differentiated structures important to GBM pathology like vasculature and meninges. Lack of vasculature severely limits the size of the organoid. Hypoxia and the absence of nutrients for cells more than 300-500 μm from the surface result in a necrotic core. Due to size limitations, this model only mirrors the human fetal cerebral cortex up to the second trimester, rendering it ineffective for studying tumor pathology in adults (262). Linkous et al. (252) created a model that includes SVZ zone markers, but for the developing brain only. Additionally, no structural or cytoarchitectural analysis of the region confirms an accurately simulated human SVZ (252). Other cerebral organoid models do not demonstrate the presence of a subventricular zone-like region altogether (235, 236, 250, 251, 253, 263). A model that accurately recapitulates the structure, cytoarchitecture, and molecular patterns of the SVZ is necessary for a more comprehensive understanding of GBM initiation and recurrence (Figure 3).

**FINAL REMARKS/CONCLUSION**

The recent evidence is in support of NSCs in the SVZ as the cells of origin of GBM, however, the astrocyte dedifferentiation hypothesis has not been rejected and in fact, gliomagenesis can certainly be a combination of oncogenic differentiation and dedifferentiation events. In addition to the site of origin, the SVZ may be involved in the recurrence of GBM as evidenced by improved PFS with radiation therapy to the ipsilateral SVZ (217). Modeling of this region could provide great insight into the pathology of GBM. Such a model could enable therapeutic testing in vivo, allowing for the creation of an individualized treatment profile specifically targeting the culprit cells for recurrence (264). Organoid modeling is an all-humanoid and
3D system, an intriguing adjunct model system for brain cancers as opposed to xenotransplantation in animal models and 2D cultures (37). In this review we discuss the role of the subventricular zone in glioblastoma genesis, maintenance, and modeling. We also pointed out the potential impact of introducing novel iPSC-based cerebral organoid SVZ models in the study of gliomagenesis. This is an exciting field of research and may lead to a more personalized approach since iPSC-based models can readily be patient-tailored. It is certain that the SVZ in general and particularly its role in cancer is not entirely understood to date; and it will remain of great interest across various fields of study such as neuroscience, neurodegeneration, and cancer research.

REFERENCES

1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neurol Oncol (2013) 15:411–56. doi: 10.1093/neuonc/not151
2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathol (2016) 131:803–20. doi: 10.1007/s00401-016-1545-1
3. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, et al. Radial Glia Cells Are Candidate Stem Cells of Ependymoma. Cancer Cell (2005) 8:323–35. doi: 10.1016/j.ccr.2005.09.001
4. Castillo M, Stem Cells, Radial Gial Cells, and a Unified Origin of Brain Tumors. Am J Neuroradiol (2010) 31:389–90. doi: 10.3174/jnr.A1674
5. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved Survival Time Trends for Glioblastoma Using the SEER 17 Population-Based Registries. J Neurooncol (2012) 107:207–12. doi: 10.1007/s11060-011-0738-7
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma Multiforme at First Relapse: Effect on Neurological Functioning, Radiother Oncol (2010) 107:294–300. doi: 10.1016/j.radonc.2010.07.032
7. MacLeod G, Bozek DA, Rajakulendran N, Monteiro V, Ahmad M, Steinhart Z, et al. Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. Cell Rep (2019) 27:971–86.e9. doi: 10.1016/j.celrep.2019.03.047
8. Wang Y, Yang J, Zheng H, Tomasek OJ, Zhang P, McKeever PE, et al. Expression of Mutant P53 Proteins Implicates a Lineage Relationship Between Neural Stem Cells and Malignant Astrocytic Glioma in a Murine Model. Cancer Cell (2009) 15:514–26. doi: 10.1016/j.ccell.2009.04.001
9. Yang ZJ, Ellis T, Markant SL, Read T-A, Kessler JD, Bourboulas M, et al. Medulloblastoma Can Be Initiated by Deletion of Patched in Lineage-Restricted Progenitors or Stem Cells. Cancer Cell (2008) 14:135–45. doi: 10.1016/j.ccr.2008.07.003
10. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen A-J, et al. P53 and Pten Control Neural and Glioma Stem/Progenitor Cell Renewal and Differentiation. Nature (2008) 455:1129–33. doi: 10.1038/nature07443
11. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, et al. Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient. PloS Med (2009) 6:e1000029. doi: 10.1371/journal.pmed.1000029
12. Kataoka A, Ishii S, Fujisada K, et al. Long-Distance Neuronal Migration in the Adult Rat. Brain Res (2009) 1268:39–48. doi: 10.1016/j.brainres.2009.03.009
13. Beiriger et al. Subventricular Zone in Glioblastoma Genesis

AUTHOR CONTRIBUTIONS
Conception and design: PZ. Interpretation of data: PZ and JB. Drafted the manuscript: JB and AH. Approved the final version to be published: PZ. Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: PZ.

FUNDING
UPMC University of Pittsburgh medical center startup funds.
31. Pilkington GJ. Cancer Stem Cells in the Mammalian Central Nervous System. *Cell Protif* (2005) 38:423–33. doi: 10.1113/jn.2005.003358.

32. Dirks PB. Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer. *J Clin Oncol Off J Am Soc Clin Oncol* (2008) 26:2916–24. doi: 10.1200/JCO.2008.17.6792.

33. Sanai H, Tramontin AD, Quinones-Hinojosa A, Barobo NM, Gupta N, Kunwar S, et al. Unique Astrocyte Ribbon in Adult Human Brain Contains Neural Stem Cells But Lacks Chain Migration. *Nature* (2004) 427:740–4. doi: 10.1038/nnature2301.

34. Dahiya S, Lee DY, Gutmann DH. Comparative Characterization of the Adult Mammalian Brain. *Neuron* (2008) 58:832–5. doi: 10.1016/j.neuron.2008.05.031.

35. Altmann C, Keller S, Schmidt MHH. The Role of Svz Stem Cells in the Adult Mammalian Brain. *J Neurosci.17-13-05046.1997*.

36. Kawamura Y, Takouda J, Yoshimoto K, Nakashima K. New Aspects of Glioblastoma-Initiating Cells: Relationship with Neural Stem Cells and the Micro-Environment. *Dev Neurosci* (2011) 33:e10498. doi: 10.1159/0003386.

37. Azzarelli R, Organoid Models of Glioblastoma to Study Brain Tumor Stem Cells. *Front Cell Dev Biol* (2020) 8. doi: 10.3389/fcell.2020.00220.

38. Lee JH, Lee JE, Kang JY, Kim SH, Park JS, Yoon SJ, et al. Human Glioblastoma Arises From Subventricular Zone Cells With Low-Level Driver Mutations. *Nature* (2018) 560:243–7. doi: 10.1038/s41586-018-0389-3.

39. Altman C, Keller S, Schmidt MHH. The Role of Svo Stem Cells in Glioblastoma. *Cancers* (Basel) (2019) 11:448. doi: 10.3390/cancers11040448.

40. Goffart N, Kroonen J, Rogister B. Glioblastoma-Initiating Cells: Relationship of SOCS3 Inhibits Astrogliogenesis and Promotes Maintenance of Neural Stem Cells. *J Neurosci* (2018) 17:30–52. doi: 10.1523/jneurosci.2018.04.007.

41. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a Cancer Stem Cell in Human Brain Tumors. *Cancer Res* (2003) 63:5821–8.

42. Kawamura Y, Takoua J, Yoshimoto K, Nakashima K. New Aspects of Glioblastoma Multiforme Revealed by Similarities Between Neural and Cancer Cells. *Acta Neuropathol* (2010) 30:8613–23. doi: 10.1523/NEUROGLIOL5272.99-2010.

43. Goffart N, Kroonen J, Rogister B. Glioblastoma-Initiating Cells: Relationship of SOCS3 Inhibits Astrogliogenesis and Promotes Maintenance of Neural Stem Cells. *J Neurosci* (2018) 17:30–52. doi: 10.1523/jneurosci.2018.04.007.

44. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a Cancer Stem Cell in Human Brain Tumors. *Cancer Res* (2003) 63:5821–8.

45. Kawamura Y, Takoua J, Yoshimoto K, Nakashima K. New Aspects of Glioblastoma Multiforme Revealed by Similarities Between Neural and Cancer Cells. *Acta Neuropathol* (2010) 30:8613–23. doi: 10.1523/NEUROGLIOL5272.99-2010.
Patients With PTEN-Coexpressing Glioblastomas. Stem Cells (2008) 26:3018–26. doi: 10.1003/stemcells.2008-0459

71. Fareh M, Turchi L, Virolle Y, Debruyne D, Almairac F, de-la-Forest Divonne S, et al. The miR-302-367 Cluster Dramatically Affects Self-Renewal and Infiltration Properties of Glioma-Initiating Cells Through CXC4R Repression and Consequent Disruption of the SHH-GLI-NANOG Network. Cell Death Differ (2012) 19:232–44. doi: 10.1038/cdd.2011.89

72. Hu Q, Zhang L, Wen J, Wang S, Li M, Feng R, et al. The EGF Receptor-Sox2-Egf Receptor Feedback Loop Positively Regulates the Self-Renewal of Neural Precursor Cells. Stem Cells (2010) 28:279–86. doi: 10.1002/stem.246

73. Ayuso-Sacido A, Roy NS, Schwartz TH, Greenfield JP, Boocock JA. Long-Term Expansion of Adult Human Brain Subventricular Zone Precursors. Neurosurgery (2008) 62:223–31. doi: 10.1227/01.NEU.0000311081.50648.AC

74. Shetty A, Dasari S, Banerjee S, Ghewala T, Zheng G, Chen A, et al. Hepatoma-Derived Growth Factor: A Survival-Related Protein in Prostate Oncogenesis and a Potential Target for Vitamin K2. Urol Oncol Semin Orig Invest (2016) 34:483.e1–8. doi: 10.1016/j.urolonc.2016.05.027

75. Uyama H, Tomita Y, Nakamura H, Nakamura S, Zhang B, Hoshida Y, et al. Expression of Hepatoma-Derived Growth Factor in Prostate Cancer. Biochim Biophys Acta - Mol Cell Res (2009) 1793:264–72. doi: 10.1016/j.bbapap.2008.09.005

76. Tsai HE, Wu J-C, Kung M-L, Liu L-F, Kuo L-H, Kuo H-M, et al. Up-Regulation of Hepatoma-Derived Growth Factor Facilitates Tumor Progression in Malignant Melanoma. PloS One (2013) 8:e59345. doi: 10.1371/journal.pone.0059345

77. Ren H, Tang X, Lee J-J, Feng L, Everett AD, Hong WK, et al. Expression of Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Patients With Pancreatic Cancer. Clin Cancer Res (2006) 12:6043–8. doi: 10.1158/1078-0432.CCR-06-1064

78. Tavazoie M, van der Veken L, Silva-Vargas V, Louissaint M, Colonna L, Zaidi B, et al. A Specialized Vascular Niche for Adult Neural Stem Cells. Cell Stem Cell (2008) 3:279–88. doi: 10.1016/j.stem.2008.07.025

79. Hu H, Tomaszewicz H, Rutishauser U. The Role of Polysialic Acid in Migration of Olfactory Bulb Interneuron Precursors in the Subventricular Zone. Neuroreport (1996) 7:279–88. doi: 10.1097/00001208-199608001-00004

80. Lozano X, D'Agostino DD, Zaidi B, et al. SVZ Stem Cells Lie in a Vascular Niche: A Quantitative Analysis of Niche Cell-Cell Interactions. Cell Stem Cell (2008) 3:289–300. doi: 10.1016/j.stem.2008.07.026

81. Luo J, Shook BA, Daniels SR, Conover JC. Subventricular Zone-Mediated Ependymary Repair in the Adult Mammalian Brain. J Neurosci (2016) 28:3804–13. doi: 10.1523/JNEUROSCI.0224-08.2008

82. Li G, et al. Autocrine Factors Sustain Glioblastoma Stem Cell Self-Renewal. Nat Neurosci (2003) 6:223–31. doi: 10.1038/nn80094-X

83. Tavazoie M, van der Veken L, Silva-Vargas V, Louissaint M, Colonna L, Zaidi B, et al. Specialized Vascular Niche for Adult Neural Stem Cells. Cell Stem Cell (2008) 3:279–88. doi: 10.1016/j.stem.2008.07.025

84. Luo J, Shook BA, Daniels SR, Conover JC. Subventricular Zone-Mediated Ependymary Repair in the Adult Mammalian Brain. J Neurosci (2016) 28:3804–13. doi: 10.1523/JNEUROSCI.0224-08.2008

85. Lichti CF, Liu H, Shavkunov AS, Mostovenko E, Sulman EP, Ezhilarasan R, et al. Quiliones-Hinojosa A, Sanai N, Gonzalez-Perez O, Garcia-Verduco JM. The Human Brain Subventricular Zone: Stem Cells in This Niche and Its Organization. Neurosurg Clin North Am (2007) 18:15–20. doi: 10.1016/j.necan.2006.10.013

86. Garcia-Verduco JM, Doetsch F, Wichterle H, Lim DA, Alvarez-Buylla A. Architecture and Cell Types of the Adult Subventricular Zone: In Search of the Stem Cells. J Neurobiol (1998) 38:234–48. doi: 10.1002/(SICI)1097-4695 (199808)38:234<234::AID-AUDI103.0.CO;2-E

87. Ren H, Tang X, Lee J-J, Feng L, Everett AD, Hong WK, et al. Expression of Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Patients With Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol (2004) 22:3230–7. doi: 10.1200/JCO.2004.02.080

88. Yang Z, Ming GL, Song H. Postnatal Neurogenesis in the Human Forebrain: Roles of Continuous Neurogenesis in the Structural and Functional Integrity of the Adult Forebrain. Proc Natl Acad Sci USA (1996) 93:14895–900. doi: 10.1073/pnas.93.25.14895

89. Lim DA, Alvarez-Buylla A. The Adult Ventricular–Subventricular Zone (V-SVZ) and Olfactory Bulb (OB) Neurogenesis. Cold Spring Harbour Perspect Biol (2016) 8:a018820. doi: 10.1101/cshperspect.a018820

90. Quiliones-Hinojosa A, Sanai N, Gonzalez-Perez O, Garcia-Verduco JM. The Human Brain Subventricular Zone: Stem Cells in This Niche and Its Organization. Neurosurg Clin North Am (2007) 18:15–20. doi: 10.1016/j.necan.2006.10.013

91. Garcia-Verduco JM, Doetsch F, Wichterle H, Lim DA, Alvarez-Buylla A. Architecture and Cell Types of the Adult Subventricular Zone: In Search of the Stem Cells. J Neurobiol (1998) 38:234–48. doi: 10.1002/(SICI)1097-4695 (199808)38:234<234::AID-AUDI103.0.CO;2-E

92. Luo J, Daniels SB, Lennington JB, Notti RQ, Conover JC. The Aging Neurogenic Subventricular Zone. Aging Cell (2006) 5:139–52. doi: 10.1111/j.1474-9726.2006.00197.x

93. Doetsch F, Alvarez-Buylla A. Network of Tangential Pathways for Neuronal Migration in Adult Mammalian Brain. Proc Natl Acad Sci USA (1996) 93:14895–900. doi: 10.1073/pnas.93.25.14895

94. Garcia-Verduco JM, Alvarez-Buylla A. Direct Evidence for Homotypic, Glia-Independent Neuronal Migration. Neuron (1997) 18:779–91. doi: 10.1016/S0896-6273(00)80317-7

95. Maki T, Liang AC, Miyamoto N, Loc EH, Arai K. Mechanisms of Oligodendrocyte Degeneration From Ventricular-Subventricular Zone-Derived Progenitor Cells in White Matter Diseases. Front Cell Neurosci (2013) 7. doi: 10.3389/fncel.2013.00275

96. Doetsch F, Alvarez-Buylla A. Network of Tangential Pathways for Neuronal Migration in Adult Mammalian Brain. Proc Natl Acad Sci USA (1996) 93:14895–900. doi: 10.1073/pnas.93.25.14895

97. Doetsch F, Alvarez-Buylla A. Network of Tangential Pathways for Neuronal Migration in Adult Mammalian Brain. Proc Natl Acad Sci USA (1996) 93:14895–900. doi: 10.1073/pnas.93.25.14895

98. Lozano X, D'Agostino DD, Zaidi B, et al. SVZ Stem Cells Lie in a Vascular Niche: A Quantitative Analysis of Niche Cell-Cell Interactions. Cell Stem Cell (2008) 3:289–300. doi: 10.1016/j.stem.2008.07.026
Unknown Inteurrenum Types. Nat Neurosci (2014) 17:207–14. doi: 10.1038/nn.3610

110. Aita-Buylla A, Garcia-Verdugo JM. Neurogenesis in Adult Subventricular Zone. J Neurosci (2002) 22:629–34. doi: 10.1523/JNEUROSCI.22-03-00629.2002

111. Ernst A, Frisen J. Adult Neurogenesis in Humans—Common and Unique Traits in Mammals. PLoS Biol (2015) 13:e1002045. doi: 10.1371/journal.pbio.1002045

112. Knott R, Singe I, Ditter M, Pantazis G, Capetian P, Meyer RP, et al. Murine Features of Neurogenesis in the Human Hippocampus Across the Lifespan From 0 to 100 Years. PLoS One (2010) 5:e8809. doi: 10.1371/journal.pone.0008809

113. Paez-Gonzalez P, Asrican B, Rodriguez E, Kuo CT. Identification of Distinct CHAT+ Neurons and Activity-Dependent Control of Postnatal SVZ Neurogenesis. Nat Neurosci (2014) 17:934–42. doi: 10.1038/nn.3734

114. Pilz GA, Jessberger S. ChAT Me Up: How Neurons Control Stem Cells. Nat Neurosci (2014) 17:897–8. doi: 10.1038/nn.3746

115. Tong CK, Chen J, Cebrian-Silla A, Mirzadeh Z, Oberneir K, CD G, et al. Axonal Control of the Adult Neural Stem Cell Niche. Cell Stem Cell (2014) 14:500–11. doi: 10.1016/j.stem.2014.01.014

116. Young SZ, Taylor MM, Bordey A. Neurotransmitters Couple Brain Activity to Subventricular Zone Neurogenesis. Eur J Neurosci (2011) 33:1123–32. doi: 10.1111/j.1460-9568.2011.07611.x

117. Huwsman E, Uylings HBM, Hoogland PV. A 100% Increase of Dopaminergic Cells in the Olfactory Bulb May Explain Hyposmia in Parkinson’s Disease. Mov Disord (2004) 19:687–92. doi: 10.1002/mds.10713

118. Maheu ME, Devorak J, Freibauer A, Davoli MA, Turecki G, Mechawar N. Fractones: Extracellular Matrix Niche Controlling Stem Cell Fate Signaling in the Mouse. Science (2004) 304:237–41. doi: 10.1126/science.3045206

119. Kornack DR, Rakic P. The Generation, Migration, and Differentiation of Olfactory Neurons in the Adult Primate Brain. Proc Natl Acad Sci USA (2001) 104:423–33. doi: 10.1073/pnas.081074998

120. Blakemore WF. The Ultrastructure of the Subependymal Plate in the Rat. J Anat (1969) 127:497–5. doi: 10.1046/j.1460-7417.1974.d0179400

121. Lewis PD. Mitotic Activity in the Primate Subependymal Layer and the Genesis of Gliomas. Nature (1968) 169:69–84. doi: 10.1046/j.1460-7417.1974.d0179400

122. Blakemore WF, Jolly RD. The Subependymal Plate and Associated Ependyma in the Dog. An Ultrastructural Study. J Neurocytol (1972) 57:269–77. doi: 10.1007/BF01098647

123. McDermott KGW, Lantos PL. Cell Proliferation in the Subependymal Layer of the Postnatal Marmoset, Callithrix Jaccus. Dev Brain Res (1990) 41:131–7. doi: 10.1016/0165-5728(90)90053-2

124. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn A-M, Nordborg C, Peterson DA, et al. Neurogenesis in the Adult Human Hippocampus. Nat Med (1998) 46:110–20. doi: 10.1038/3305

125. Huang L, DeVries GJ, Bittman EL. Photoperiod Regulates Neuronal Brain-Derived Neurotrophic Factor Signaling. J Cell Biol (2005) 168:415–27. doi: 10.1083/jcb.200407053

126. Gould E, Reeves AJ, Graziano MSA, Gross CG. Neurogenesis in the Striatum and Neocortex of Adult Macaque Monkeys After Global Cerebral Ischemia. J Neurosci (2005) 81:776–88. doi: 10.1016/j.jnrd.2006

127. Luzzati F, De Marchis S, Aslao F, Peretto P. Neurogenesis in the Caudate Nucleus of the Adult Rabbit. J Neurosci (2006) 26:6609–21. doi: 10.1523/JNEUROSCI.4731-05.2006

128. Inta D, Alfonso J, von Engelhardt J, Kreuzberg MM, Meyer AH, van Hooft JA, et al. Neurogenesis and Widespread Forebrain Migration of Distinct GABAergic Neurons From the Postnatal Subventricular Zone. Proc Natl Acad Sci USA (2008) 105:20994–9. doi: 10.1073/pnas.0807059105

129. Bergmann O, Spalding KL, Frise AE, Beiriger et al. Subventricular Zone in Glioblastoma Genesis. Nat J. Adult Neurogenesis in Humans- Cold Spring Harb Perspect Med (2015) 7:a018994. doi: 10.1101/cshperspect.a018994

130. Magnusson JP, Goritz C, Tatarishvili J, DO D, Smith EMK, Lindvall O, et al. A Latent Neurogenic Program in Astrocytes Regulated by Notch Signaling in the Mouse. Science (2010) 334:237–41. doi: 10.1126/science.3646206

131. Baker KL, Daniels SB, Lenington JB, Lardaro T, Czap A, Notti RQ, et al. Neuroblast Protophages in the Subventricular Zone of the Regenerative Nervous System. J Comp Neurol (2006) 498:747–61. doi: 10.1002/cne.21090

132. Snapyan M, Lemasson M, Bril MS, Blais M, Massouh M, Ninkovic J, et al. GABAergic Neurons From the Postnatal Subventricular Zone. J Neurosci (2009) 29:4172–88. doi: 10.1523/JNEUROSCI.4956-08.2009

133. Kokovey E, Gomer E, Wang Y, Lotz S, Lin G, Sun Y, et al. Adult SVZ Lineage Cells Home to and Leave the Vascular Niche via Differential Responses to SDF1/CXCR4 Signaling. Cell Stem Cell (2010) 7:163–73. doi: 10.1016/j.stem.2010.05.019

134. Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, et al. Endothelial Cells Stimulate Self-Renewal and Expand Neurogenesis of Neural Stem Cells. Science (2004) 7:163–73. doi: 10.1126/science.1095505

135. Kerever A, Schnack J, Vellinga D, Ichikawa N, Arikawa-Hirasawa M, et al. Adult Neurogenesis in Humans- Common and Unique Traits in Mammals. PloS Biol (2014) 7:a018994. doi: 10.1371/journal.pbio.1002045

136. Mirzadeh Z, Merkle FT, Soriano-Navarro M, Garcia-Verdugo JM, Alvarez-Buylla A. Neural Stem Cells Confer Unique Pinkwheel Architecture to the Outer Subventricular Zone Promotes Enlargement and Gyrification of Different Precursors. J Cell Biol (2005) 168:415–27. doi: 10.1083/jcb.200407053
the Primate Cerebrum. *Proc Natl Acad Sci USA* (2011) 108:7589–94. doi: 10.1073/pnas.1201847110

151. Arnedo FA, Carvalho-LIB, Grinberg LT, Farfel JM, Ferretti REL, Leite REP, et al. Equal Numbers of Neuronal and Nonneuronal Cells Make the Human Brain an Isometrically Scaled-Up Primate Brain. *J Comp Neurol* (2009) 513:332–41. doi: 10.1002/cne.21974

152. Gabi M, Collins CE, Wong P, Torres LB, Kaas JH, Herculano-Houzel S. Cell Types, Lineage, and Architecture of the Germinal Zone in the Adult Dentate Gyrus. *J Comp Neurol* (2004) 478:359–78. doi: 10.1002/cne.20288

153. Aguirre A, Gallo V. Postnatal Neurogenesis and Gliogenesis in the Olfactory Bulb From NG2-Expressing Progenitors of the Subventricular Zone. *J Neurosci* (2004) 24:10530–41. doi: 10.1523/JNEUROSCI.3572-04.2004

154. Nait-Oumesmar B, Picard-Riera N, Kerninnon C, Baron-Van Evercooren A. The Role of SVZ-Derived Neural Precursors in Demyelinating Diseases: From Animal Models to Multiple Sclerosis. *J Neurol Sci* (2008) 265:26–31. doi: 10.1016/j.jns.2007.09.032

155. Christie KJ, Turnley AM. Regulation of Endogenous Neural Stem/Progenitor Cells for Neural Repair - Factors That Promote Neurogenesis and Gliogenesis in the Normal and Damaged Brain. *Front Cell Neurosci* (2012) 6. doi: 10.3389/fncel.2012.00070

156. Romanko MJ, et al. Roles of the Mammalian Subventricular Zone in Cell Replacement After Brain Injury. *Prog Neurobiol* (2004) 74:77–99. doi: 10.1016/j.pneurobio.2004.07.001

157. Al-Dhalhmi M, Beveridge M,Soares L, Nicholson J, Draijer S, Mundim M, Lu VM, et al. Galectin-3 Modulates Postnatal Subventricular Zone Gliogenesis. *Glia* (2020) 68:435–50. doi: 10.1002/glia.23730

158. Nefelt C, Lafay J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. (2019) 178:835–49.e21. doi: 10.1002/glia.201906.0204.

159. Liu C, Sage JC, Miller MR, Verhaak RGW, Hippmeyner S, Vogel H, et al. Mosaic Analysis With Double Markers Reveals Tumor Cell of Origin in Glioma. *Cell* (2011) 146:209–21. doi: 10.1016/j.cell.2011.06.014

160. Haskins WE, Zablotsky BL, Foret MR, Ihrie RA, Alvarez-Buylla A, Eisenman RN, et al. Secreted Factors From Brain Endothelial Cells Maintain Glioblastoma Stem-Like Oligodendrocyte Progenitors of the mTOR Pathway. *EMBO Rep* (2011) 12:470–6. doi: 10.1038/embo.2011.39

161. Imai Y, Kohsaka S. Intracellular Signaling in M-CSF-Induced Microglia Activation: Role of Iba1. *GLIA* (2004) 50:164–74. doi: 10.1002/glia.10149

162. Jung K, Mock A, Enzer J, Geisenberger C, Warta R, Capper D, et al. Spatial Invasion-Spared Brain Region. *Anat Rec* (2014) 297:106–10. doi: 10.1002/ar.22709

163. Gollapalli K, Ghantia S, Kumar S, Srivastava R, Rapole S, Mistry A, et al. Subventricular Zone Involvement in Glioblastoma – A Proteomic Evaluation and Clinicoradiological Correlation. *Sci Rep* (2017) 7:1449. doi: 10.1038/s41598-017-01202-8

164. Yamaki T, Shibahara I, Matsuda K, Kanemura Y, Konta T, Kanamori M, et al. Relationships Between Recurrence Patterns and Subventricular Zone Involvement or CD133 Expression in Glioblastoma. *J Neurooncol* (2020) 146:489–99. doi: 10.1007/s10937-019-02381-y

165. Adelberg S, Bostel T, Konig L, Welzel T, Debus J, Combs SE. A Comparison of Long-Term Survivors and Short-Term Survivors With Glioblastoma, Subventricular Zone Involvement: A Predictive Factor for Survival? *Radiat Oncol* (2014) 9:95. doi: 10.1186/1748-717X-9-95

166. Willard N, Kanchanakul K. Massive Dissemination of Adult Neural Stem Cells, Lineage, and Architecture of the Germinal Zone in the Adult Dentate Gyrus. *J Comp Neurol* (2013) 566:13–28. doi: 10.1002/cne.23749

167. Iacoangeli M, Rienzo D, Colasanti R, Gladi M, Alvaro L, et al. Endothelial Cells Create a Stem Cell Niche in Glioblastoma by Providing NOTCH Ligands That Nurture Self-Renewal of Cancer Stem-Like Cells. *Cancer Res* (2011) 71:6061–72. doi: 10.1158/0008-5472.CAN-10-4269

168. Mughal AA, Zhang L, Fayzullin A, Server A, Li Y, Wu Y, et al. Patterns of Invasive Growth in Malignant Gliomas—The Hippocampus Emerges as an Invasion-Spared Brain Region. *Neoplasia (United States)* (2018) 20:643–56. doi: 10.1080/15280418.2018.1433240

169. Palmer TD, Willhoite AR, Gage FH. Vascular Niche for Adult Hippocampal Neurogenesis. *J Comp Neurol* (2000) 425:479–94. doi: 10.1002/1096-9861(20001002)425:4<479:AID-CNE2>3.0.CO;2-3
191. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clin Cancer Res (2009) 15:6602–7. doi: 10.1158/1078-0432.CCR-09-0715
192. Ohgaki H, Kleihues P, The Definition of Primary and Secondary Glioblastoma. *Clin Cancer Res* (2013) 19:764–72. doi: 10.1158/1078-0432.CCR-12-3002
193. Duan S, Yuan G, Liu X, Ren R, Li J, Zhang W, et al. PTEN Deficiency Reprogrammes Human Neural Stem Cells Towards a Glioblastoma Stem Cell-Like Phenotype. *Nat Commun* (2013) 6:11006. doi: 10.1038/ncomms10668
194. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The Somatic Genomic Landscape of Glioblastoma. *Cell* (2013) 155:462–77. doi: 10.1016/j.cell.2013.09.034
195. Renault VA, et al. Overexpression of PTEN in Adult But Not Embryonic Neural Stem Cells: Implication for the Genesis of Glioblastomas. *Mol Cell Neurosci* (2001) 16:2649–58. doi: 10.1016/S1044-7494(01)00016-8
196. Ohgaki H, Kleihues P, Ourinamic Study of TERT Promoter Mutations in Human Cancers. *Nat Commun* (2013) 4:2185. doi: 10.1038/ncomms3185
197. Cantanhede IG, De Oliveira JR. PDGF Family Expression in Glioblastoma Multiforme: Data Compilation From Iyv Glioblastoma Atlas Project Database. *Sci Rep* (2017) 7:15271. doi: 10.1038/s41598-017-15045-w
198. Wechsler-Reya R, Scott MP. The Developmental Biology of Brain Tumors. *Mol Cell Neurosci* (2001) 24:385–428. doi: 10.1006/mcne.2001.1006
199. Van Lookeren Campagne M, Gill R. Tumor-Suppressor P53 Is Expressed in Embryonic Progenitor Cell Produces Neurons and Astrocytes. *J Neurosci* (1992) 12:4565–74. doi: 10.1523/nerousci.12-11-04565.1992
200. Craig CG, Tropepe V, Morshead C, Reynolds B, Weiss S, van der Kooy D. Endogenous Hepatocyte Growth Factor Is a Niche Signal for Subventricular Zone Neural Stem Cell Amplification and Self-Renewal. *Sci Cell* (2003) 23:693–708. doi: 10.1016/j.cell.2003.09.014
201. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 Mutations as Predictive Factor of Secondary Glioblastomas. *Mol Cell Neurosci* (2001) 16:2649–58. doi: 10.1016/S1044-7494(01)00016-8
202. Qian Z, Ren L, Wu D, Yang X, Zhou Z, Nie Q, et al. The Relationship Between Radiation Dose to Neural Stem Cell Niches and Survival of GBM. *Int J Radiat Oncol Biol Phys* (2014) 90:S283–4. doi: 10.1016/j.ijrobp.2014.09.065
203. Ohgaki H, Kleihues P, The Definition of Primary and Secondary Glioblastoma. *Clin Cancer Res* (2009) 15:6602–7. doi: 10.1158/1078-0432.CCR-09-0715
204. Renault VA, et al. Overexpression of PTEN in Adult But Not Embryonic Neural Stem Cells: Implication for the Genesis of Glioblastomas. *Mol Cell Neurosci* (2001) 16:2649–58. doi: 10.1016/S1044-7494(01)00016-8
205. Renault VA, et al. Overexpression of PTEN in Adult But Not Embryonic Neural Stem Cells: Implication for the Genesis of Glioblastomas. *Mol Cell Neurosci* (2001) 16:2649–58. doi: 10.1016/S1044-7494(01)00016-8
206. Cantanhede IG, De Oliveira JR. PDGF Family Expression in Glioblastoma Multiforme: Data Compilation From Iyv Glioblastoma Atlas Project Database. *Sci Rep* (2017) 7:15271. doi: 10.1038/s41598-017-15045-w
207. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A. Pdgfrα-Positive B Cells Are Neural Stem Cells in the Adult SVZ That Form Glioma-Like Growths in Response to Increased PDGF Signaling. *Neuron* (2006) 51:187–99. doi: 10.1016/j.neuron.2006.06.012
208. Gil-Perotin S, Haines JD, Kaur J, Marin-Husstege M, Spinetta MJ, Kim K-H, et al. CXCL12 Mediates Glioblastoma Resistance to Radiotherapy in the Subventricular Zone. *Acta Pathol Microbiol Scand A* (2012) 120:4565–74. doi: 10.1152/nerousci.12-11-04565.1992
244. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, et al. Early
Independent Symmetrical Self-Renewal of a Mammalian Tissue Stem Cell.
PloS Biol (2005) 3:e283. doi: 10.1371/journal.pbio.0030283

245. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis
et al. H3.3K27M Cooperates With Trp53 Loss and PDGFRA Gain in Mouse
Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas.
Cell Stem Cell (2011) 23:1220–41. doi: 10.1016/j.stem.2011.04.007

246. Ogawa J, Pao GM, Shokhirev MN, Verma IM. Glioblastoma Model Using
Lentiviral Vectors.
Oncogene Subgroups According to Molecular and Phenotypic Criteria. Oncogene
(2008) 27:2897–9. doi: 10.1038/sj.onc.1210194

247. Bardella C, Al-Dalahmah O, Krell D, Brazauskas P, Al-Qahtani K, Tomkova
M, et al. Expression of Id1hR132H in the Murine Subventricular Zone Stem
Cell Niche Recapitulates Features of Early Gliomagenesis. Cancer Cell (2016)
30:578–94. doi: 10.1016/j.ccell.2016.08.017

248. Jacques TS, Swales A, Brzozowski MJ, Herreraquez NV, Linehan JM, Mirzadeh
Z, et al. Combinations of Genetic Mutations in the Adult Neural Stem Cell
Compartment Determine Tumour Phenotypes. EMBO J (2010)
29:222–35. doi: 10.1038/emboj2009.327

249. Lancaster MA, Renner M, Martin C-A, Wenzel D, Bicknell LS, Hurles ME,
et al. Cerebral Organoids Model Human Brain Development and Microcephaly.
Nature (2013) 501:373–9. doi: 10.1038/nature12517

250. Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC, et al. A
Three-Dimensional Organoid Culture System Derived From Human
Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell
Heterogeneity of Tumors Found In Vivo. Cancer Res (2016) 76:2465–77.
doi: 10.1158/0008-5472.CAN-15-2402

251. Jacob F, Salinas RD, Zhang DY, Nguyen PT, Schnoll JW, SzGH, et al. A
Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates
Inter- and Intra-Tumoral Heterogeneity. Cell (2020) 180:188–204.e22.
doi: 10.1016/j.cell.2019.11.036

252. Linkous A, Balamasitas D, Snuderl M, Edwards L, Miyaguchi K, Milner T,
et al. Modeling Patient-Derived Glioblastoma With Cerebral Organoids. Cell
Rep (2019) 26:48–63.e6. doi: 10.1016/j.celrep.2019.02.063

253. Yi HG, Jeong YH, Kim Y, Choi Y-J, Moon HE, Park SH, et al. A Bioprinted
Human Glioblastoma-on-a-Chip for the Identification of Patient-Specific
Responses to Chemoradiotherapy. Nat Biomed Eng (2019) 3:509–19.
doi: 10.1038/s41551-019-0363-x

254. Bhandari A, Di Lullo E, Jung D, Muller S, Crouch EE, Espinosa CA, et al. Outer
Radial Glia-Like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma.
Cell Stem Cell (2020) 26:48–63.e6. doi: 10.1016/j.stem.2019.11.015

255. Ballabio C, Anderle M, Gianesello M, Lago C, Miele E, Cardano M, et al.
Modeling Medulloblastoma In Vivo and With Human Cerebellar Organoids.
Nat Commun (2020) 11:5583. doi: 10.1038/s41467-019-13989-3

256. Dias C, Guillenot F. Revealing the Inner Workings of Organoids. EMBO J
(2017) 36:1299–1301. doi: 10.15252/embj.201796860

257. Muguruma K, Nishiyama A, Kawakami H, Hashimoto K, Sasai Y.
Self-Organization of Polarized Cerebellar Tissue in 3D Culture of Human
Puripotent Stem Cells. Cell Rep (2015) 10:537–50. doi: 10.1016/j.celrep.2014.
12.051

258. Renner M, Lancaster MA, Bian S, Choi H, Ku T, Peer A, et al. Self-Organized
Developmental Patterning and Differentiation in Cerebral Organoids. EMBO J
(2017) 36:1316–29. doi: 10.15252/embj.201694700

259. Kim J, Koo BK, Knoblch JA. Human Organoids: Model Systems for Human
Biology and Medicine. Nat Rev Mol Cell Biol (2020) 21:571–84. doi: 10.1038/
s41598-020-0259-3

260. Chen Z, Hambardzumyan D. Immune Microenvironment in Glioblastoma
Subtypes. Front Immunol (2018) 9. doi: 10.3389/fimmu.2018.00104

261. Li Y, Zhang P, Cai S, Peng J, Hua G. Organoid Based Personalized Medicine:
From Bench to Bedside. Cell Regener (2020) 9:21. doi: 10.1186/s13619-020-
00059-z

262. Qian X, Jacob F, Salinas RD, Zhang DY, Nguyen PT, Schnoll JW, et al. A
Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates
Inter- and Intra-Tumoral Heterogeneity. Cell (2020) 180:188–204.e22.
doi: 10.1016/j.cell.2019.11.036

Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those
of the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Beiriger, Habib, Jovanovich, Kodavali, Edwards, Amankalor and Zinn. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.